Regeneron Pharmaceuticals Inc at Wells Fargo Healthcare Conference Transcript
Good morning. My name is Mohit Bansal. I'm one of the biopharma analysts here at Wells Fargo, and I'm very happy to start with Regeneron Pharmaceuticals today.
We have Marion McCourt, Head of Commercial at Regeneron, and Ryan Crowe, Head of Investor Relations. Thank you very much for joining us. Over to you, Ryan.
Thanks, Mohit, and it's great to be here. I always love coming to this conference. It's our second year in a row here, and I'm very excited to be here again.
I'd like to remind you that our remarks today may include forward-looking statements about Regeneron. Each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in such statements. A description of material risks and uncertainties can be found on Regeneron's SEC filings.
Regeneron does not undertake any obligation to update any forward
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
